GSK (GSK) Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference summary
Event summary combining transcript, slides, and related documents.
Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference summary
9 Sep, 2026Strategic priorities and operational changes
New CEO prioritized accelerating R&D, fueling product launches, and simplifying operations, including forming a Strategic Portfolio Review Group and a parallel simplification group leveraging technology and AI.
Nearly GBP 2 billion in targeted savings, with most reinvested into the pipeline, supporting a doubling of phase III trial starts and margin stability during key patent expiries.
Relocation of U.K. R&D to Cambridge aims to leverage the biotech ecosystem, academic partnerships, and faster translational medicine.
Expansion of business development capabilities in the U.S., China, and Europe, with significant deals in oncology and respiratory.
Pipeline and product innovation
HIV franchise is shifting from daily tablets to long-acting injectables, with launches planned for every four and six months dosing, supported by strong patient and physician preference data.
Patent protection for key HIV assets is being extended through new combinations and next-generation products, with new assets offering fresh patent estates.
Oncology pipeline strengthened by the Nuvalent acquisition, bringing late-stage assets for non-small cell lung cancer and expanding into multiple tumor types with antibody-drug conjugates.
Liver disease innovation highlighted by bepirovirsen, offering a functional cure for hepatitis B and fast-track designations in major markets.
Commercial performance and market opportunities
SHINGRIX vaccine continues strong growth, with high efficacy and expanding penetration in the U.S., Europe, and China, and ongoing studies for label expansion into cardiovascular and dementia benefits.
Exdensur, a new asthma biologic, offers twice-yearly dosing and significant reduction in hospitalizations, targeting both bio-naive and existing biologic patients.
Commercial focus on specialty products is expected to support margin stability and improvement, especially through the 2028-2030 HIV patent expiry period.
Latest events from GSK
- GBP 1.9bn savings and 22 Phase III starts fuel a >GBP 40bn 2031 sales ambition.GSK
J.P. Morgan UK Leaders Conference - Four- and six-month HIV regimens, pipeline launches and oncology aim to sustain growth through expiries.GSK
Jefferies Global Healthcare Conference - Biomarker-led R&D advances long-acting airway therapies and novel liver programs.GSK
3rd Annual Guggenheim Healthcare Innovation Conference - Specialty-led growth and pipeline investment support reaffirmed FY26 guidance.GSK
Q3 2026 - Oncology data highlighted gains across ADCs, immunotherapy and targeted therapies.GSK
ESMO 2026 Investor Briefing - 14% CER sales growth and upgraded outlooks to >£38bn sales by 2031.GSK
Q4 2023 - Ultra-long-acting biologics, AI-driven R&D, and global partnerships are shaping future growth.GSK
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - GBP 1.9bn in savings will fund pipeline growth, with oncology and specialty assets prioritized.GSK
Bank of America Global Healthcare Conference - Rapid portfolio growth and robust clinical data position oncology for major advances by 2031.GSK
Morgan Stanley 24th Annual Global Healthcare Conference